Drug Trial Radar · NCT04817189
Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)
Last checked: Nov 20, 2026Latest source record: Dec 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
414
Actual
Start
Feb 1, 2021
Primary completion
Jul 2, 2024
Study completion Jul 2, 2024
Sponsor
- Lead sponsor
- Helsinn Healthcare SAIndustry
- Sponsor type
- Industry
- First posted
- Mar 26, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Supportive care
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
MyRisk: Efficacy and safety evaluation of oral Akynzeo® in patients receiving MEC at high risk of developing CINV based on a prediction tool. A multinational and multicenter study. Antiemetic guidelines recommendations are based on the emetogenic potential of the chemotherapy. Chemotherapy (CT) agents are divided in Highly, Moderately, Low and Minimally Emetogenic potential. In addition to type of chemotherapy, several patient-related risk factors can increase the risk of CINV (chemotherapy-induced nausea and vomiting). Currently, there is limited consensus surrounding the most relevant patient risk factors that may predict the risk of CINV. Based on a recent study by Dranitsaris et al. (Dranitsaris et al. Ann Oncol. 2017 Jun 1; 28(6):1260-1267.), eight (8) predictive factors have been identified and an algorithm has been developed to incorporate these factors into the optimal selection of prophylactic antiemetics: 1. nausea and/or vomiting in the prior cycle of chemotherapy 2. use of non-prescribed antiemetics at home in the prior cycle of chemotherapy 3. platinum or anthracycline-based chemotherapy 4. age \< 60 years 5. expectations for (anticipating) nausea and/or vomiting 6. \<7 h of sleep the night before chemotherapy 7. history of morning sickness during previous pregnancy 8. cycle of chemotherapy (A negative association between risk and number of cycles was identified where the hazard for CINV was highest in cycles 1 and 2, with a gradual decline and plateau from cycle 3 onward). The clinical application of this prediction tool has the potential to be an important resource for clinicians and may help to enhance patient care by optimizing the use of the antiemetics in a proactive manner.
Conditions
- Chemotherapy-induced Nausea and Vomiting
Interventions
NEPA (300mg netupitant/0.5mg palonosetron)Drug
Oral netupitant/palonosetron (300 mg/0.50 mg) fixed-dose combination on Day 1 of each cycle.
Granisetron, 2 mg (oral) or 1 mg (IV) OR Palonosetron, 0.5 mg (oral), 0.25mg (IV) OR Ondansetron, 16 mg (oral) or 8 mg (IV) OR Dolasetron 100 mg (oral) OR Tropisetron 5 mg (oral or IV)Drug
Standard of care will be administered on Day 1 of each cycle.
Dexamethasone, 8 mg (oral) or equivalent IV doseDrug
Dexamethasone (8 mg) will be administered on Day 1 of each cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Probability of Complete Responses Over Three Cycles of Chemotherapy After the Start of the MEC AdministrationTime frame: At the end of all three chemotherapy cycles. The length of a cycle depends on the treatment being given (cycles range from 2 to 6 weeks).
Locations
19 sites in 7 countries. Site status is shown where the registry gives one.
Shanghai Chest Hospital
Shanghai, China
Shanghai Ninth People´s Hospital
Shanghai, China
Shanghai Obstetrics and Gynecology Hospital
Shanghai, China
Thomayerova nemocnice
Prague, Czechia
General University Hospital in Prague
Prague, Czechia
Evang. Kliniken Essen-Mitte
Essen, Germany
Universitätsmedizin Mannheim
Mannheim, Germany
München Klinik Neuperlach
München, Germany
Frauenklinik St. Louise
Paderborn, Germany
Klinikum Ernst von Bergmann gemeinnützige GmbH
Potsdam, Germany
Sotiria General Hospital, 3rd Deúpartment of Medicine, School of Medicine, National and Kapodistrian University of Athens
Athens, Greece
General University Hospital of Heraklion
Heraklion, Greece
Complejo Hospitalario Universitario de A Coruña
A Coruña, Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
Hospital General Universitario Gregorio Marañón
Madrid, Spain
Hospital Universitario de Salamanca
Salamanca, Spain
University Hospital Basel
Basel, Switzerland
Swiss Medical Network - Clinique de Genolier
Genolier, Switzerland
The Royal Marsden Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.